The NIA-AA ATN research framework focuses on the diagnosis of AD with biomarkers in living persons, which shifts the definition of AD in living ..
people from a symptomatic to a biological construct. The ATN framework is a method to classify and characterize disease presence/state through evaluation of β amyloid deposition (A), pathologic tau (T), and neurodegeneration (N). In this webinar, we will present the best practices of amyloid PET imaging and the most recent developments in the tau PET imaging space, including quantitative and visual assessment paradigms per the latest FDA approval. We will examine imaging of neurodegeneration and also explore emerging biomarkers beyond N. Techniques such as bi-compartment diffusion modeling, quantitative susceptibility mapping (QSM), arterial spin labeling (ASL), and breath-hold fMRI are capable of being deployed in a large-scale clinical trial setting and could aid patient selection and demonstrate therapeutic benefit. We will also highlight emerging PET markers for α-synuclein, microgliosis, and synaptic density, and their role in further refining AD staging. The webinar will also explore how the multi-modal integration of molecular imaging, MRI, and fluid biomarkers can provide a robust ability to accurately parse patients along the AD cascade to provide optimal classification and treatment strategies as well as therapeutic efficacy.